Firdapse (Amifampridine Phosphate) Patent Expiration, LOE Window & CMS Spending

Firdapse (Amifampridine Phosphate) by Catalyst: FDA Orange Book LOE 2037-02-25, 0 AB generics, $204.2M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCatalyst
FDA Application & PathwayN208078 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2037-02-25
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$204.2M
2024 Medicare Part D Spend$177.8M
2024 Medicaid Spend$26.4M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 21.4% 2-yr change)